QIAGEN N.V. QGEN, together with Myriad Genetics MYGN, will develop a globally distributable kit-based test for analyzing Homologous Recombination Deficiency (HRD) status. The endeavor expands upon the ...
Next-generation-sequencing-based homologous recombination deficiency (HRD) assay based on QIAGEN’s QIAseq xHYB technology, QIAGEN Digital Insight solutions, and Myriad’s proprietary, FDA-approved ...
As the number of monkeypox cases around the world has ballooned since early May, so too has the list of diagnostic developers rapidly churning out tests for the virus. Unlike many of the other ...
Germantown, Maryland, and Venlo, the Netherlands, June 03, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the QIAstat-Dx Gastrointestinal ...
Molecular diagnostics company Qiagen launched the first syndromic test that differentiates between monkeypox and five other viruses with similar symptoms. The QIAstat-Dx Viral Vesicular Panel is ...
HILDEN, Germany & GERMANTOWN, Md,--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the QIAstat-Dx Viral Vesicular Panel RUO, the first syndromic ...
QIAGEN’s New Generation of QuantiFERON TB Test Gains Chinese Approval and Renewed WHO Recommendation
QuantiFERON-TB Gold Plus (QFT-Plus), the fourth generation of the modern gold standard for TB detection, receives Chinese NMPA approval as test for active tuberculosis detection World Health ...
Medical testing company Qiagen is joining forces with the International Panel Physicians Association (IPPA) to boost awareness around tuberculosis testing. Qiagen currently markets the QuantiFERON-TB ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results